North America Alzheimer’s Disease Therapeutics & Diagnostics Market Forecast 2022-2030
KEY FINDINGS
The North America Alzheimer’s disease therapeutics & diagnostics market is predicted to increase with a 6.46% CAGR between the estimated years 2022 and 2030. Due to anticipated sales growth and the prospect of new therapies gaining market approval, the market is surging in the region.
MARKET INSIGHTS
The North America Alzheimer’s disease therapeutics & diagnostics market growth evaluation entails the analysis of Canada and United States. According to the Alzheimer Society of Canada, thousands of new cases of dementia are diagnosed every year. By 2031, the number is expected to increase by 66%.
Since currently available drugs are unable to cure the disease, the benefits of these drugs gradually decrease with time. Further private and public insurers limit drug coverage for individuals who meet the insurance conditions. Therefore, the provincial government steps in and is responsible for Canada’s healthcare facilities, which boosts the healthcare industry.
Moreover, advocacy groups like the Alzheimer’s Society of Canada are also trying to improve drug coverage. Thus, owing to all the factors above, the Canadian market for Alzheimer’s disease diagnostics and therapeutics is expected to register healthy growth over the forecast period.
COMPETITIVE INSIGHTS
Some of the leading companies in the market include Eli Lilly & Company, Baxter International Inc, Johnson & Johnson, GE Healthcare, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
- 1. Research Scope & Methodology
- 1.1. Study Objectives
- 1.2. Scope Of Study
- 1.3. Methodology
- 1.4. Assumptions & Limitations
- 2. Executive Summary
- 2.1. Market Size & Estimates
- 2.2. Market Overview
- 3. Market Dynamics
- 3.1. Parent Market Analysis
- 3.2. Key Drivers
- 3.2.1. Growing Geriatric Population
- 3.2.2. Rising Pervasiveness Of Alzheimer’s Disease
- 3.2.3. Emerging Novel Diagnostic Technologies
- 3.2.4. Increasing Pipeline Drugs
- 3.3. Key Restraints
- 3.3.1. Failure Of The Late-stage Drugs
- 3.3.2. Stringent Government Regulations
- 3.3.3. Lack Of The Availability Of Surrogate Markers
- 4. Key Analytics
- 4.1. Timeline Of Alzheimer’s Disease Therapeutics & Diagnostics Market
- 4.2. Phases And Sternness Of Alzheimer’s Disease
- 4.3. Impact Of Covid-19 On Alzheimer’s Disease Therapeutics & Diagnostics Market
- 4.4. Key Market Trends
- 4.5. Porter’s Five Forces Analysis
- 4.5.1. Buyers Power
- 4.5.2. Suppliers Power
- 4.5.3. Substitution
- 4.5.4. New Entrants
- 4.5.5. Industry Rivalry
- 4.6. Key Buying Criteria
- 4.7. Supply Chain Analysis
- 4.8. Opportunity Matrix
- 4.9. Vendor Landscape
- 5. Market By Therapeutics & Diagnostics
- 5.1. Therapeutics
- 5.1.1. Drugs
- 5.1.1.1. Marketed Drugs
- 5.1.1.2. Pipeline Drugs
- 5.1.2. Disease Stage
- 5.1.2.1. Late-stage: Severe Ad
- 5.1.2.2. Early/Middle Stage: Mild To Moderate Ad
- 5.1.2.3. Prodromal Stage
- 5.1.3. Generic & Branded
- 5.1.3.1. Branded
- 5.1.3.2. Generic
- 5.2. Diagnostics
- 5.2.1. Lumbar Puncture Test
- 5.2.2. Positron Emission Tomography
- 5.2.3. Electroencephalography
- 5.2.4. Magnetic Resonance Imaging
- 5.2.5. Computed Tomography
- 5.2.6. Blood Test
- 5.2.7. Other Diagnostics
- 6. Geographical Analysis
- 6.1. North America
- 6.1.1. Market Size & Estimates
- 6.1.2. Key Growth Enablers
- 6.1.3. Key Challenges
- 6.1.4. Key Players
- 6.1.5. Country Analysis
- 6.1.5.1. United States
- 6.1.5.2. Canada
- 7. Competitive Landscape
- 7.1. Key Strategic Developments
- 7.1.1. Mergers & Acquisitions
- 7.1.2. Product Launches & Developments
- 7.1.3. Partnerships & Agreements
- 7.1.4. Business Expansions, Announcements, & Divestitures
- 7.2. Company Profiles
- 7.2.1. Allergan Plc (Acquired By Abbvie)
- 7.2.2. Amarantus Bioscience Holdings Inc
- 7.2.3. Baxter International Inc
- 7.2.4. Biogen Inc
- 7.2.5. Cognoptix Inc
- 7.2.6. Eisai Co Ltd
- 7.2.7. Eli Lilly & Company
- 7.2.8. F Hoffmann-la Roche
- 7.2.9. Ge Healthcare
- 7.2.10. Johnson & Johnson
- 7.2.11. Lupin Limited
- 7.2.12. Merck & Co Inc
- 7.2.13. Novartis Ag
- 7.2.14. Pfizer Inc
- 7.2.15. Siemens Healthineers Ag
- 7.2.16. Sun Pharmaceuticals Industries Ltd
- 7.2.17. Teva Pharmaceutical Industries Limited
- 7.2.18. Zydus Cadila
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook